Rosiglitazone

Rosiglitazone is an anti-diabetic drug from the thiazolidinedione class. It is being marketed as Avandia® by the pharmaceutical company GlaxoSmithKline, both as a standalone preparation and in combination with metformin (Avandamet®).

Related Topics:
Anti-diabetic drug - Thiazolidinedione - Pharmaceutical company - GlaxoSmithKline - Metformin

~ ~ ~ ~ ~ ~ ~ ~ ~ ~

Like other thiazolidinediones, its mechanism of action is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a pure ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone (Mohanty et al).

Related Topics:
Thiazolidinedione - Intracellular receptor - Peroxisome proliferator-activated receptor - Insulin resistance - Inflammatory

~ ~ ~ ~ ~ ~ ~ ~ ~ ~